Abstract
It is estimated that a third of the worlds population is currently infected with tuberculosis, leading to 1.6 million deaths annually. The current drug regimen is 40 years old and takes 6-9 months to administer. In addition, the emergence of drug resistant strains and HIV co-infection mean that there is an urgent need for new anti-tuberculosis drugs. The twenty-first century has seen a revival in research and development activity in this area, with several new drug candidates entering clinical trials. This review considers new potential firstline anti-tuberculosis drug candidates, in particular those with novel mechanisms of action, as these are most likely to prove effective against resistant strains. A brief overview of current first-line and recent drugs (such as fluoroquinolones, rifampicin and isoniazid analogues) is initially presented. This is followed by a description of structure-activity relationships, in vitro and in vivo activity, pharmacokinetics, mechanism of action, combination regimens and clinical trials of the new drug candidates SQ109, PA-824, OPC-67683, TMC207 and others.
Keywords: Mycobacterium tuberculosis, drug action, SQ109, PA-824, OPC-67683, TMC207/R207910
Current Medicinal Chemistry
Title: New Anti-Tuberculosis Drugs with Novel Mechanisms of Action
Volume: 15 Issue: 19
Author(s): Emma C. Rivers and Ricardo L. Mancera
Affiliation:
Keywords: Mycobacterium tuberculosis, drug action, SQ109, PA-824, OPC-67683, TMC207/R207910
Abstract: It is estimated that a third of the worlds population is currently infected with tuberculosis, leading to 1.6 million deaths annually. The current drug regimen is 40 years old and takes 6-9 months to administer. In addition, the emergence of drug resistant strains and HIV co-infection mean that there is an urgent need for new anti-tuberculosis drugs. The twenty-first century has seen a revival in research and development activity in this area, with several new drug candidates entering clinical trials. This review considers new potential firstline anti-tuberculosis drug candidates, in particular those with novel mechanisms of action, as these are most likely to prove effective against resistant strains. A brief overview of current first-line and recent drugs (such as fluoroquinolones, rifampicin and isoniazid analogues) is initially presented. This is followed by a description of structure-activity relationships, in vitro and in vivo activity, pharmacokinetics, mechanism of action, combination regimens and clinical trials of the new drug candidates SQ109, PA-824, OPC-67683, TMC207 and others.
Export Options
About this article
Cite this article as:
Rivers C. Emma and Mancera L. Ricardo, New Anti-Tuberculosis Drugs with Novel Mechanisms of Action, Current Medicinal Chemistry 2008; 15 (19) . https://dx.doi.org/10.2174/092986708785132906
DOI https://dx.doi.org/10.2174/092986708785132906 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Selection of Microbial T-Cell Epitopes for Immune-Diagnosis, Immune- Therapy and Vaccine Design
Current Pharmacogenomics Evolution of the DUT Gene: Horizontal Transfer between Host and Pathogen in all Three Domains of Life
Current Protein & Peptide Science Chemical Constituents of Plants from the Genus Valeriana
Mini-Reviews in Organic Chemistry Polysaccharides to Combat Viruses (COVID-19) and Microbes: New updates
Current Molecular Pharmacology Resistant TB: Newer Drugs and Community Approach
Recent Patents on Anti-Infective Drug Discovery The Impending Renaissance in Discovery & Development of Natural Products
Current Topics in Medicinal Chemistry The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) 1,2,5-Thiadiazole Scaffold: A Review on Recent Progress in Biological Activities
Combinatorial Chemistry & High Throughput Screening Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science Ketamine as Antidepressant? Current State and Future Perspectives
Current Neuropharmacology Mini Heme-Proteins: Designability of Structure and Diversity of Functions
Current Protein & Peptide Science Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review
Current Medicinal Chemistry Biological Properties of Yeast-based Mannoprotein for Prospective Biomedical Applications
Combinatorial Chemistry & High Throughput Screening Meet the Editorial Board:
Current Medicinal Chemistry Supercritical Fluid Particle Design of DPI Formulations (Review)
Current Pharmaceutical Design Synthesis, Characterization, Antimycobacterial and Anticancer Evaluation of New 1,2,4-Triazole Derivatives
Letters in Drug Design & Discovery Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science New Antimicrobial Approaches: Reuse of Old Drugs
Current Drug Targets